GenoMed Treatment Protocols: Great Horned Owl (Modified by Environmental Risk Analysis Program)

From: David W. Moskowitz, MD, MA, FACP, (314) 983-9933
<dwmoskowitz@genomedics.com>
Date: Aug 3, 2004

Source: Excerpted from GenoMed Press Release.

[For background and additional information about GenoMed and WNV
treatment protocols, see WNV-L postings with subject line WNV Treatment
Protocols' and see full text of all GenoMed press releases at
<http://www.genomedics.com/investor/dsp_investor.cfm>. -- WNV-L
Moderator LCL]

GenoMed's Treatment Saves Country's First Great Horned Owl from
Presumed West Nile Virus Encephalitis

ST. LOUIS, MO. – August 3, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a
Next Generation Disease Management™ company that uses its expertise in
genomics to improve clinical outcomes in as many species as possible,
announced today that its patent-pending treatment appears to have saved
the country's first Great Horned Owl from presumed West Nile virus
encephalitis.

Marge Gibson, Executive Director of Raptor Education Group, Inc. in
Antigo, Wisconsin (www.raptoreducationgroup.org) is using GenoMed's
approach to treat American bald eagles and other large raptors. On July
21st, a female Great Horned Owl was brought in. The owl was sick, lying
down frequently and having occasional seizures. The owl turned her head
constantly and her eyes were unfocused, suggesting that she had
vestibular neuritis, or inflammation of the balancing organ of the
brain. She acted dazed and refused to eat on her own. She had to be
tube-fed. Last Friday, July 29th, Ms. Gibson was finally able to get a
sample of an angiotensin II receptor blocker (ARB), and gave a dose to
the owl. In Ms. Gibson's experience, no Great Horned Owl had ever
survived West Nile virus before.

The next morning, Ms. Gibson came in to euthanize the owl, assuming it
would be even closer to death. But the Great Horned Owl was standing in
her cage with her eyes focused for the first time, and her head held
still. When Ms. Gibson offered it a dead mouse she had in her hand for
another patient, the owl gobbled it down, followed quickly by another
mouse.

Ms. Gibson quickly emailed other raptor rescue groups about the good
news.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer,
"West Nile virus encephalitis looks the same under the microscope in
different species. So we'd been hoping that the same treatment would
work for birds and horses, as well as for people with an intact immune
system. It's reassuring to have dramatic confirmation like this. The
response in immunocompetent humans has been just as fast."

Added Dr. Moskowitz, "I really hope more people will hear about our
free trial. Every death from West Nile virus saddens me. I can't help
thinking, 'If only that person or their family member or friend had
heard about our trial in time.' "

To enroll in GenoMed's free trial, just click on the "West Nile trial"
link at http://www.genomedics.com.

Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained
for seven years in Internal Medicine, Biochemistry, and Nephrology at
Washington University School of Medicine in St. Louis before spending
11 years on the faculty of St. Louis University School of Medicine. He
is a pioneer in the field of medical genomics, and has been recognized
for his groundbreaking treatment of diseases associated with the
angiotensin I-converting enzyme, such as chronic renal failure due to
hypertension or type II diabetes. Dr. Moskowitz’s research on viruses,
including West Nile virus, avian influenza ("bird flu"), and SARS, is
regarded as an innovative approach for otherwise incurable diseases.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
WESTNILEVIRUS-L is an email discussion group for communication
and discussion about West Nile Virus, particularly regarding policy,
risk reduction and public education issues. It is moderated by
Dr. Lois Levitan, Program Leader of the Cornell University
Environmental Risk Analysis Program (ERAP).
To subscribe (or unsubscribe), send an email request with your name
and contact information to <envrisk@cornell.edu>.
To receive messages once a day in digest format, subscribers can
send an email to <listproc@cornell.edu> with message:
"set WESTNILEVIRUS-L mail digest-nomime".

Subscribers are encouraged to post to the group by sending
messages to <envrisk@cornell.edu>. Put "WNV Listserv" in
the subject line and send unformatted text, without attachments.
Received on Tue Jul 13 09:31:32 2004